Sachpekidis C, et al. - The potential role of quantitative analysis of 2-deoxy-2-(¹⁸F) fluoro-d-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) data in the monitoring of patients with metastatic melanoma undergoing ipilimumab therapy was assessed in this investigation. In the result, they did not find statistically significant differences between patients demonstrating clinical benefit (CB) and those demonstrating no CB, regarding either semi-quantitative or quantitative parameters in all scans. In treatment response evaluation of metastatic melanoma patients receiving ipilimumab, quantitative analysis of ¹⁸F-FDG PET data did not provide additional information. Data reported that PET response evaluation criteria for immunotherapy criteria correlated better with clinical response.